Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) just unveiled an update.
Thiogenesis Therapeutics announced that CEO Patrice Rioux will present clinical updates on its lead candidate TTI-0102 at the United Mitochondrial Disease Foundation’s 2026 Bench-to-Bedside webinar, including results from a recently completed Phase 2 trial in MELAS conducted at European academic centers and plans for a U.S. Phase 2a trial in Leigh syndrome spectrum expected to start in the first quarter of 2026 with a leading pediatric hospital. By highlighting progress in two ultra-rare mitochondrial disorders that currently lack approved treatments, the company is underscoring both the potential of TTI-0102 to address mitochondrial oxidative stress and its ambition to build a differentiated position in the niche but high-need market for pediatric and inherited mitochondrial diseases.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp. is a San Diego-based, clinical-stage biopharmaceutical company developing next-generation sulfur-containing prodrugs as precursors to approved thiol-active compounds, targeting serious pediatric and other rare diseases driven by mitochondrial dysfunction and oxidative stress. Its lead candidate, TTI-0102, is a cysteamine-based prodrug in Phase 2 development for MELAS, with additional planned trials in Leigh syndrome spectrum and pediatric MASH, positioning the company in the rare mitochondrial and metabolic disease markets where there are currently no approved therapies for several indications.
Average Trading Volume: 24,131
Technical Sentiment Signal: Sell
Current Market Cap: C$33.69M
For a thorough assessment of TTI stock, go to TipRanks’ Stock Analysis page.